Details for Patent: 9,539,251
✉ Email this page to a colleague
Which drugs does patent 9,539,251 protect, and when does it expire?
Patent 9,539,251 protects VENCLEXTA and is included in one NDA.
This patent has twenty-one patent family members in ten countries.
Summary for Patent: 9,539,251
| Title: | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
| Abstract: | The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. |
| Inventor(s): | Sampath; Deepak (South San Francisco, CA), Klein; Christian (Iffeldorf, DE), Fairbrother; Wayne John (South San Francisco, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) F. Hoffmann-La Roche AG (Basel, CH) |
| Application Number: | 14/020,761 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,539,251 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,539,251
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER | ⤷ Try a Trial | ||||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER | ⤷ Try a Trial | ||||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,539,251
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2884307 | ⤷ Try a Trial | |||
| China | 104768581 | ⤷ Try a Trial | |||
| China | 111437386 | ⤷ Try a Trial | |||
| China | 111481552 | ⤷ Try a Trial | |||
| European Patent Office | 2892557 | ⤷ Try a Trial | |||
| European Patent Office | 3919079 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
